SCHEMBL26611154

SCHEMBL26611154

CC(N[S@+]([O-])C(C)(C)C)c1cccc(C(F)(F)C2CC3CCC(C2)N3C(=O)OC(C)(C)C)c1F

nearest known ligand 0.37

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ CHRM3 P20309 1/20 0.37
▸ HSD11B1 P28845 1/20 0.34
▸ GPR119 Q8TDV5 17/20 0.33
▸ MMP13 P45452 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26611156 1.00 CHRM2 (0.37) CHRM2CHRM1CHRM3HSD11B1GPR119
SCHEMBL26611151 1.00 CHRM2 (0.37) CHRM2CHRM1CHRM3HSD11B1GPR119
SCHEMBL27149273 0.89 SOS1 (0.31) —
SCHEMBL27149271 0.89 SOS1 (0.31) —
SCHEMBL27149272 0.89 SOS1 (0.31) —
SCHEMBL26610918 0.84 CHRM2 (0.43) CHRM2CHRM1CHRM3HSD11B1GPR119
SCHEMBL26610917 0.84 CHRM2 (0.43) CHRM2CHRM1CHRM3HSD11B1GPR119
SCHEMBL30662889 0.84 CHRM2 (0.43) CHRM2CHRM1CHRM3HSD11B1GPR119
SCHEMBL27317073 0.78 BACE1 (0.32) —
SCHEMBL30662884 0.77 CHRM2 (0.46) CHRM2CHRM1CHRM3HSD11B1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132133-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC (US) 2026-05-14 — — US disclosed
US-12195465-B2 Macrocyclic heterocycles and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2025-01-14 — — US disclosed
US-20240208975-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-06-27 — — US disclosed
US-20230339952-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208975-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF HRAS, KRAS, TP53 CHRM2 4879/4885CHRM1 4884/4885CHRM3 4863/4885
US-20260132133-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KRAS, HRAS, BCL6 CHRM2 3897/4885CHRM1 4219/4885CHRM3 3783/4885
US-12195465-B2 Macrocyclic heterocycles and uses thereof HRAS, KRAS, TP53 CHRM2 4879/4885CHRM1 4884/4885CHRM3 4863/4885
US-20230339952-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF HRAS, KRAS, TP53 CHRM2 4879/4885CHRM1 4884/4885CHRM3 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback